You are here: Industry Insights > gilead

News List

Gilead pushes on with NASH drug after phase 2 success pharmaphorum
December 06, 2018
Gilead Sciences presented promising data on its research into advanced fibrosis caused by non-alcoholic steatohepatitis (NASH), one of several big pharma companies developing drugs for the currently untreatable disease.
China's NMPA approves Gilead's Vemlidy for HBV biospectrum
November 20, 2018
HBV is highly prevalent in China with an estimated 20 million people meeting current guidelines for therapy – accounting for almost one-third of all patients currently requiring therapy worldwide.
Gilead strikes deal with NHS England on Yescarta access pharmatimes
October 11, 2018
Gilead has struck a deal with NHS England that allows some adults with lymphoma access to its “game-changing” CAR-T therapy Yescarta.
NHS England reaches deal with Gilead on CAR-T therapy Yescarta pharmaceutical-technology
October 09, 2018
National Health Service (NHS) England has reached an agreement with Gilead Sciences to provide the pharmaceutical company’s chimeric antigen receptor T-cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) for adults with large cell lymphoma.
Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi pharmaceutical-technology
September 30, 2018
A judge from the 21st Federalist Court of Brasilia has ruled to invalidate US biopharma company Gilead’s exclusivity patent for Sovaldi (sofosbuvir), which is indicated for Hepatitis C.
Changes of the Global HIV Drug Market in 10 Years 1℃
September 30, 2018
Gilead Sitting Atop, the Quadruple Regimen Genvoya Fast Growing into a Star of Today
Gilead to release generic versions of hep C meds over a decade before patent expiry pharmafile
September 29, 2018
Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of hepatitis C, Epclusa (sofosbuvir/velpatasvir)...
Gilead to launch generic versions of hepatitis C drugs pharmaceutical-technology
September 27, 2018
Gilead Sciences has revealed plans to introduce generic versions of its Epclusa and Harvoni in the US for the treatment of chronic hepatitis C virus infection.
Gilead launches generics of own hepatitis C drugs in US to cut health costs pharmaphorum
September 27, 2018
Gilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls for lower drug prices because of spiralling healthcare costs.
Gilead to launch authorised generic versions of hepatitis C drugs Epclusa, Harvoni next year in US firstwordpharma
September 25, 2018
Gilead Sciences announced Monday that it plans to launch authorised generic versions of its hepatitis C therapies Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the US next year.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page